Patent · US Active

Exon skipping compositions for treating muscular dystrophy

US9217148B2 · kind B2 · utility

41Cited by
79References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 14, 2014
Grant dateDec 22, 2015
Priority date—
Expiry dateMar 14, 2034

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.